Endo International PLC (ENDP) Given a $10.00 Price Target by Canaccord Genuity Analysts
Endo International PLC (NASDAQ:ENDP) has been given a $10.00 price objective by equities research analysts at Canaccord Genuity in a note issued to investors on Monday. The brokerage currently has a “hold” rating on the stock. Canaccord Genuity’s price objective would suggest a potential upside of 31.23% from the company’s current price.
ENDP has been the topic of a number of other research reports. William Blair reissued a “market perform” rating on shares of Endo International PLC in a research note on Wednesday, June 14th. Stifel Nicolaus lowered Endo International PLC from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $22.00 to $15.00 in a research note on Friday, June 9th. Royal Bank Of Canada reissued a “sector perform” rating and issued a $9.00 price objective (down previously from $15.00) on shares of Endo International PLC in a research note on Wednesday, August 9th. Vetr raised Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 price objective on the stock in a research note on Wednesday, May 17th. Finally, Morgan Stanley reduced their price objective on Endo International PLC from $12.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 10th. Three research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have assigned a buy rating to the company. Endo International PLC has an average rating of “Hold” and an average target price of $14.75.
Endo International PLC (NASDAQ ENDP) opened at 7.62 on Monday. The stock’s 50 day moving average price is $10.81 and its 200-day moving average price is $11.52. The firm’s market capitalization is $1.70 billion. Endo International PLC has a one year low of $7.41 and a one year high of $24.93.
Endo International PLC (NASDAQ:ENDP) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. The business had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. Endo International PLC’s quarterly revenue was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.86 EPS. On average, equities research analysts anticipate that Endo International PLC will post $3.52 earnings per share for the current fiscal year.
In other Endo International PLC news, COO Terrance J. Coughlin purchased 20,000 shares of the stock in a transaction on Thursday, August 10th. The stock was bought at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the completion of the acquisition, the chief operating officer now directly owns 181,369 shares of the company’s stock, valued at $1,396,541.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.50% of the stock is owned by corporate insiders.
Large investors have recently made changes to their positions in the company. OppenheimerFunds Inc. increased its stake in shares of Endo International PLC by 182.9% in the first quarter. OppenheimerFunds Inc. now owns 2,873,153 shares of the company’s stock valued at $32,065,000 after buying an additional 1,857,678 shares during the period. Bank of New York Mellon Corp boosted its position in Endo International PLC by 38.7% in the first quarter. Bank of New York Mellon Corp now owns 2,271,111 shares of the company’s stock valued at $25,345,000 after buying an additional 633,904 shares in the last quarter. First Quadrant L P CA purchased a new position in Endo International PLC during the first quarter valued at $24,556,000. Teachers Advisors LLC boosted its position in Endo International PLC by 1.9% in the second quarter. Teachers Advisors LLC now owns 840,470 shares of the company’s stock valued at $9,388,000 after buying an additional 15,928 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its position in Endo International PLC by 1.6% in the second quarter. TIAA CREF Investment Management LLC now owns 649,535 shares of the company’s stock valued at $7,255,000 after buying an additional 10,387 shares in the last quarter. Institutional investors own 92.27% of the company’s stock.
About Endo International PLC
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.